Procept Biorobotics Corp
$ 27.84
2.13%
25 Feb - close price
- Market Cap 1,523,250,000 USD
- Current Price $ 27.84
- High / Low $ 28.46 / 26.66
- Stock P/E N/A
- Book Value 6.81
- EPS -1.53
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.27 %
- 52 Week High 66.85
- 52 Week Low 26.23
About
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. The company is headquartered in Redwood City, California.
Analyst Target Price
$50.73
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-07-30 | 2025-04-29 | 2025-02-25 | 2024-10-30 | 2024-08-01 | 2024-05-01 | 2024-02-27 | 2023-11-08 | 2023-07-27 | 2023-04-27 | 2023-02-28 |
| Reported EPS | -0.38 | -0.35 | -0.45 | -0.35 | -0.4 | -0.5 | -0.51 | -0.54 | -0.51 | -0.56 | -0.63 | -0.56 |
| Estimated EPS | -0.41 | -0.4125 | -0.4913 | -0.34 | -0.49 | -0.52 | -0.56 | -0.44 | -0.51 | -0.57 | -0.58 | -0.54 |
| Surprise | 0.03 | 0.0625 | 0.0413 | -0.01 | 0.09 | 0.02 | 0.05 | -0.1 | 0 | 0.01 | -0.05 | -0.02 |
| Surprise Percentage | 7.3171% | 15.1515% | 8.4063% | -2.9412% | 18.3673% | 3.8462% | 8.9286% | -22.7273% | 0% | 1.7544% | -8.6207% | -3.7037% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.3243 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PRCT
2026-02-25 22:52:36
PROCEPT BioRobotics (NASDAQ:PRCT) reported a quarterly loss of ($0.53) per share, missing consensus estimates by $0.21, and revenue of $76.38 million, falling short of the expected $93.70 million. Despite the earnings miss, the company's shares rose on heavy volume, trading at $27.84, though still below its 50 and 200-day moving averages and near its one-year low. Analysts have largely maintained a "Moderate Buy" rating, with a consensus price target of $53.40, even after some price target reductions by several firms.
2026-02-25 20:52:36
PROCEPT BioRobotics reported strong financial results for Q4 2025, with total revenue reaching $76.4 million, a 12% increase year-over-year, and a record 12,200 procedures performed. The company also provided 2026 revenue guidance of $390 million to $410 million, reflecting significant growth despite a revised handpiece sales strategy focusing on alignment with procedure volumes and higher average selling prices. This strategic realignment aims to position the company for sustainable long-term growth.
2026-02-24 20:53:27
PROCEPT BioRobotics (NASDAQ: PRCT) is scheduled to release its quarterly earnings on February 25, 2026, with analysts expecting an EPS of $-0.32. The company's past performance shows that an earnings beat in the last quarter led to a 9.74% drop in share price the following day, and shares are currently down 59.96% over the last 52 weeks. Investors will be keenly watching the earnings report and forward guidance, especially given the bearish sentiment among long-term shareholders and an average one-year price target implying potential for movement.
2026-02-23 21:03:00
PROCEPT BioRobotics (Nasdaq: PRCT) has rescheduled its fourth-quarter 2025 earnings call and Investor Day due to significant travel disruptions caused by inclement weather. The company will now report Q4 2025 results after market close on Wednesday, February 25, 2026, with the conference call at 4:30 p.m. ET. The in-person Investor Day has been moved to Thursday, February 26, 2026, at NASDAQ Headquarters in New York City.
2026-02-19 19:56:48
Procept BioRobotics (PRCT) stock has fallen to a new 52-week low of $26.65, representing a significant decline of over 59% in the past year. Despite this, InvestingPro data suggests the company is undervalued, boasts strong revenue growth of 50.07%, and holds more cash than debt. Analysts have offered mixed evaluations, with UBS initiating a 'Buy' rating and BofA Securities downgrading to 'Neutral' due to decelerating utilization growth of their aquablation technology.
2026-02-12 18:57:14
Wall Street analysts are optimistic about PROCEPT BioRobotics (PRCT) ahead of its Q4 2025 earnings report, with expectations for strong revenue and GAAP EPS. Despite one analyst maintaining a Hold rating, the majority hold Buy ratings, and the average price target suggests significant upside. The company specializes in surgical robotics for urology with its AquaBeam Robotic System.
